DNA
Ginkgo Bioworks Holdings
NYSE: DNA · HEALTHCARE · BIOTECHNOLOGY
$9.70
+14.66% today
Updated 2026-05-01
Market cap
$551.05M
P/E ratio
—
P/S ratio
3.24x
EPS (TTM)
$-5.64
Dividend yield
—
52W range
$5 – $18
Volume
1.2M
Ginkgo Bioworks Holdings (DNA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $54.18M | $76.66M | $313.84M | $477.71M | $251.46M | $227.04M | $170.16M |
| Revenue growth (YoY) | — | +41.5% | +309.4% | +52.2% | -47.4% | -9.7% | -25.1% |
| Cost of revenue | $0.00 | $15.61M | $129.69M | $204.22M | $54.01M | $38.55M | $31.52M |
| Gross profit | $54.18M | $61.05M | $184.15M | $273.49M | $197.45M | $188.49M | $138.63M |
| Gross margin | 100.0% | 79.6% | 58.7% | 57.3% | 78.5% | 83.0% | 81.5% |
| R&D | $96.30M | $159.77M | $1.15B | $1.05B | $580.62M | $424.06M | $243.77M |
| SG&A | $29.48M | $38.31M | $862.95M | $1.43B | $385.02M | $246.16M | $183.29M |
| Operating income | $-71.60M | $-137.03M | $-1.83B | $-2.21B | $-864.41M | $-559.76M | $-315.28M |
| Operating margin | -132.1% | -178.8% | -582.6% | -462.4% | -343.8% | -246.5% | -185.3% |
| EBITDA | $-106.66M | $-108.58M | $-1.81B | $-2.06B | $-821.29M | $-484.39M | $-254.61M |
| EBITDA margin | -196.8% | -141.7% | -575.7% | -431.2% | -326.6% | -213.3% | -149.6% |
| EBIT | $-117.41M | $-122.45M | $-1.84B | $-2.12B | $-892.85M | $-547.41M | $-313.60M |
| Interest expense | $2.42M | $2.38M | $2.37M | $106000.00 | $93000.00 | $94000.00 | $0.00 |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-119.33M | $-126.61M | $-1.83B | $-2.10B | $-892.87M | $-547.03M | $-312.76M |
| Net income growth (YoY) | — | -6.1% | -1345.4% | -15.0% | +57.6% | +38.7% | +42.8% |
| Profit margin | -220.2% | -165.2% | -583.1% | -440.6% | -355.1% | -240.9% | -183.8% |